In-Person CME Webcast
0.75 CME/CE Credit
Promise, Potential and Peril in Psychiatry’s Next Chapter: Ketamine, Psychedelics and Translational Neurotherapeutics
For three decades, the psychopharmacologic armamentarium for the treatment of depression and many psychiatric disorders has centered on the “Monoamine Hypothesis” – the assumption that that epinephrine, norepinephrine and dopamine comprise the neurotransmitters most influential in symptom control. Psychiatry has thus witnessed the development of many SSRIs and SNRIs that are molecular permutations of each other, with few agents presumed able to leverage novel mechanisms, and most requiring greater than 6 weeks to elicit clinical response. Ketamine, classical psychedelics, and interventional neurotherapeutics, however, may significantly change the static status quo. Within the realms of “novel/emerging” and “potential” (pipeline) interventions, mechanistically novel ketamine and esketamine have prompted cautious optimism for select patient populations; looking to the near-term future, pipeline agents MDMA and psilocybin appear poised as potential best-in-class new agents, with pivotal phase III psilocybin data expected shortly. With potential promise also comes potential peril, however. Misinformation in popular culture and social media abounds, and the dissemination of evidence-based, data-driven knowledge about these agents and psychiatry’s emerging next chapter is paramount. At this unique moment in psychiatric history, join us for a rapid overview of key agents capturing public and professional attention in a spirit of cautious optimism.
CME/CE Information
0.75 AMA PRA Category 1 Credits™ or 0.75 AANP
Release Date: 10/23/2025
Expiration Date: 12/7/2025
Faculty
Learning Objectives
- Identify the unique challenges of “translational” medicine in the current era of rapidly emerging pipeline medications and therapies, while emphasizing evidence-based practice, safety, and the impact of misinformation and regulatory gaps
- Conceptualize ketamine and esketamine as first-in-class examples of emerging translational therapies, focusing on their clinical and mechanistic novelty, evidence-based use, key indications, and side effects
- Recognize the clinical potential and mechanistic differences of next-generation, allied treatments in the translational pipeline, including psilocybin and MDMA
Faculty
Robert C. Meisner, MD
Medical Director, The McLean Ketamine Service, Program in Psychiatric Neurotherapeutics, McLean Hospital
Attending Child & Adolescent Psychiatrist, Acute Psychiatric Service, Massachusetts General Hospital, Boston, Massachusetts
Learn MoreDisclosures
All individuals in control of content for this activity (including faculty, moderator, editors, reviewers) have disclosed no relevant financial relationships.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308.
Designation Statement
This activity is approved for 0.75 contact hour, which includes 0.75 hour of pharmacology.
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.